# UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

> **NCT00869232** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Arkansas** · enrollment: 90 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Melphalan
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Cisplatin
- **DRUG:** Adriamycin
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00869232
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-10
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869232, "UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00869232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*